

ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

Company



2020/05/08 22:10:00

Price
193.02
USD

Difference 0.02%(0.03)

Chart
not available

Contact Details

ALLERGAN PLC
Daphne Karydas
Clonshaugh Business and
Technology Park
- Dublin, D17 E400, Ireland

Tel: +1-862-261-7000
Fax: -
Web:
<http://www.allergan.com>
E-mail: -

Company Profile

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model -- Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2019		2018		2017	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	11,126,700,000		6,475,400,000		11,376,700,000	
Common stock capital		0		0		0
Fixed assets	-		-		-	
Equity capital of a company		58,196,400,000		65,131,000,000		73,837,100,000
Cash and cash equivalents	2,503,300,000		880,400,000		1,817,200,000	
Accrued liabilities		-		-		-
Other assets	930,100,000		2,852,800,000		349,500,000	
Current liabilities		11,070,700,000		5,727,900,000		9,848,100,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		-		-		-
Different income		-		-		-
Other liabilities		-		-		-
Total assets	94,699,100,000	94,699,100,000	101,787,600,000	101,787,600,000	118,341,900,000	118,341,900,000

Balance notes

	2019	2018	2017
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	17,400	16,900	17,800
Equity ratio	61.48%	64.00%	62.41%
Debt-equity ratio	62.66%	56.24%	60.24%

Others

	2019	2018	2017
Tax Expense Rate	-2.86%	25.82%	64.22%

ALLERGAN PLC

ISIN: IE00BY9D5467 WKN: G0177J108 Asset Class: **Stock**

Income statement

	2019	2018	2017
Turnover	16,088,900,000	15,787,400,000	15,940,700,000
Net income	-5,271,000,000	-5,096,400,000	-4,125,500,000
EBIT	-4,019,346,250	-5,457,110,810	-8,524,657,650
Operating income before taxes	-5,118,700,000	-6,856,900,000	-10,386,400,000
Cash Flow	7,238,700,000	5,640,100,000	5,873,400,000
Net interest income	-706,200,000	-866,000,000	-1,027,900,000
Research and development expenses	1,812,000,000	2,266,200,000	2,100,100,000
Income taxes	146,400,000	-1,770,700,000	-6,670,400,000
Result from investments in subsidiaries, associates and other	-	-	-
Revenues per employee	842,263	850,932	815,752

Board of Directors

Brenton L. Saunders	Chairman of Supervisory Board
Thomas C. Freyman	Member of Supervisory Board
Robert J. Hugin	Member of Supervisory Board
Peter J. McDonnell	Member of Supervisory Board
Nesli Basgoz	Member of Supervisory Board
Michael E. Greenberg	Member of Supervisory Board
Joseph H. Boccuzzi	Member of Supervisory Board
Christopher W. Bodine	Member of Supervisory Board
Christopher J. Coughlin	Member of Supervisory Board
Carol Anthony (John) Davidson	Member of Supervisory Board
Adriane M. Brown	Member of Supervisory Board

Members of Management Board

Brenton L. Saunders	Chairman of Managing Board
Wayne R. Swanton	Member of Executive Committee
Matt Walsh	Member of Executive Committee
Kellie Sears	Member of Executive Committee
Bob Bailey	Member of Executive Committee
Bill Meury	Member of Executive Committee
Alex Kelly	Member of Executive Committee
C. David Nicholson	Member of Executive Committee